July27Unitedkingdom  2021 


Abstract Volume: 3 Issue: 1 ISSN:

COVID-19 and Antihistaminic Medicines - Improving the Health of Millions by Strategically Disseminating a "Simple but Potential Solution"

Magdalena Filcek1*, Dr Mayank Vats2, Anna Skrzyniarz Plutecka3

1.Specialist Neuro-architecture, Master of Interior Architecture, innovator of many patented projects as innovative system Vinci Power Nap® - Dream’s Space® and the Balonodrom Project©, Wroclaw, Poland.

2.Senior Specialist - Interventional Pulmonologist, Pulmonologist, Intensivist & Sleep Physician at Rashid Hospital, Dubai, UAE.

3.Head of Anesthesiology and Intensive Care Department, Masovian Oncology Hospital, Wieliszew, Warsaw University Maria Sklodowska-Curie, Specialist in Anesthesiology and Intensive Care and with experience in Infectious Diseases. Poland.


Corresponding Author: Magdalena Filcek, Specialist Neuro-architecture, Master of Interior Architecture, innovator of many patented projects as innovative system Vinci Power Nap® - Dream’s Space® and the Balonodrom Project©, Wroclaw, Poland.

Copy Right: © 2021 Magdalena Filcek. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received Date: June 16, 2021

Published date: July 01, 2021


This article aims to present the analysis of pathophysiological mechanism of COVID-19 as conclusion of review based on the available literature and research about COVID-19 and to help support the treatment protocol of COVID-19 patients based on the established pathophysiology of COVID-19 hyper inflammation. The proposed changes relate to the use of antihistamines in the prevention and treatment as well as changing the procedures of mechanical ventilation of the patient.

COVID-19 and Antihistaminic Medicines - Improving the Health of Millions by Strategically Disseminating a "Simple but Potential Solution"


The proposal to adapt the new procedures is dictated by the targeting of the COVID-19 symptom development mechanism, which has not been taken into account in the public discourse so far, and whose key is the activation of mast cells, which are part of the immune system, and the release of histamine, which acts as a mediator of inflammatory processes, the highest concentration of which occurs in the skin, lungs, nasal mucosa and stomach. [1]

The SARS-CoV-2 virus after entering the body initiates the activation of mast cells to release large amounts of histamine from the granules, which by affecting the H1, H2, H3, H4 receptors [2,3,4], causes an allergic and pseudo-allergic reaction called histamine intolerance (HIT) [5,6,7,8]. Avalanche histamine ejection and stimulation of the above-mentioned receptors, among others leads to: bronchospasm, cough, shortness of breath, increase in platelet aggregation, decrease in saturation, tachycardia, vasodilation and increase in their permeability, edema, diarrhea, hypotension, characteristic severe fatigue, fever, headache, neurological changes, as well as multi-organ changes including hyper inflammation in the lungs, intestines, heart, kidneys, liver [9]. The above symptoms of a systemic inflammatory reaction are also observed in the developing COVID-19 and its complications [10].

The consequence of the unstoppable cascade of the histamine reaction is a decrease in saturation and breathing difficulties, which leads to the need for oxygen therapy and in the advanced stage to the mechanical ventilation, which extremely often leads to ventilator associated pneumonia (VAP) [11,12,13,14]. Patients, with bypassed nose air flow aerodynamics [15], in most cases are ventilated with cold [16,17] and dry air [18,19], regarding its difference with body temperature, the air reaches excessively high pressures in the lungs due to Charle’s Law [20], these physical factors leads to nonspecific degranulation of mast cells and the release of further doses of histamine [21,22], provoked respiratory and other symptoms [23,24,25,26,27]. For proper oxgen- CO2 exchange in lungs there is required temperature 37ºC and 100% humidity (44mg/L) [28,29,30]. The colder air together with too high pressure and viruses, among other, are activators for mast cells [31,32,33,34,35] that are massively present in the lungs [36,37]. As a result, it leads to irreversible damage to the pulmonary parenchyma such as inflammation, fibrosis and barotrauma [38,39,40,41].

Histamine exerting a physiological effect through its four H1-H4 receptors coupled with G-protein, entering the bloodstream, causes a systemic inflammatory response syndrome and multi-organ failure that can lead to life-threatening conditions or even death, and in cases of chronic could initiate autoimmune diseases [42,43,44,45,46,47].


Based on analyzes of the literature, available to date, in the fields of COVID-19 and the treatment of patients with viral diseases, histamine intolerance and others, as well as experts consultations in the field of pulmonology, anesthesiology, allergology, physics, chemistry, technical issues of ventilators, genetics, with current and past research published about histamine, confirmed cases, it can be concluded that antihistamines [48,49], blocking H1-H4 receptors, used preventively, at the first symptoms and during the development of the disease, can stop the cascade of reactions in the form of a storm histamine- cytokine [50,51], thus the progression of COVID-19 and protect many patients from mechanical ventilation.

Considering presented hypothesis of histamine pathophysiology, the Indian Premiere Medical Institute has incorporated antihistamine in the treatment protocol of COVID-19 patients. In UAE also significant improvements has been observed in the symptomatology of COVID-19 patients viz cough, throat irritation and breathlessness after application of antyhistamines. Although histamines levels were not measured but addition of antihistamines with consequent improvement in symptoms reflects involvement if histamine pathway in COVID-19 pathophysiology and systemic inflammatory response, which was also confirmed in the ICU cases of the hospital in Wieliszew in Poland.


Among the well-established inflammatory mechanism of COVID-19 induced multi-organ dysfunction including prothrombotic stage, hypercoagulability, cytokine storm and direct vascular injury, we suggest role of histamine mechanism also as a significant contributory cause of inflammatory organ dysfunction. Consider replacing the passive Heat Moisture Exchanger (HME) [52,53,54] with an active Moisture Heater (HH) on ventilators, as required device in each ventilator to warm and humidify of the air up to requisite levels [55,56], revise also if the volume of air is setting to the appropriate base of the patient body mass (not total body mass) [57]. In addition, attention should be paid to the level of histamine neutralizing enzymes such as DAO and HMNT, provide them if possible and support their synthesis with supplementation [58].

Of course, the use of the established hypothesis and research does not automatically guarantee obtaining the same results in all patients and the further extensive research work including large randomized controlled trails should be carried out on large number of COVID-19 patients to establish the exact role of histamine and beneficial effects of targeted antihistaminic medicine to prevent the COVID-19 induced inflammatory multi-organ damage.



[1] B.T.Elden et al. „The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hunt for New Therapeutic Targets” 13 August 2018.

[2] M.E.Parsons, C.R. Ganellin „Histamine and its receptors” January 2006.

[3] M.Cataldi et al ”Histamine receptors and antihistamines: from discovery to clinical applications”  22 May 2014.

[4] C.A.Akdis,et al. „Histamine receptors are hot in immunopharmacology” March 2006.

[5] L. Maintz, N.Novak, „Histamine and histamine intolerance” May 2007 AmJ Clin Nutr. 85(5):1185-1196.

[6] M.Gotz „[Pseudo-allergies are due to histamine intolerance]” 1996.

[7] K.Mukai et al. „IgE and mast cells in host defense against parasites and venoms” 25 May 2016.

[8] A.B.Kay „Allergy and allergic diseases. First of two parts” 4 January 2001.

[9] Dr. D. Jernigan „Histamine Intolerance; The Cause of Hundreds of Symptoms” https://www.marioninstitute.org/histamine-intolerance-syndrome/

[10] „COVID Overview - Symptoms Common Symptoms” CDC Symptom Self-Checker May 2020.

[11] Ch-E. Luyt, T. Sahnoun, M.Gautier, et al „Ventilator-associated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: a retrospective cohort study”  23 November 2020.

[12] J.Lee „Hypersensitivity Pneumonitis” September 2019.

[13] F.Álvarez-Lerma, M.Palomar-Martínez, et al. „Prevention of ventilator-associated pneumonia: The Multimodal Approach of the Spanish ICU “Pneumonia Zero” Program* February 2018.

[14] M.Maes, E.Higginson, J.Pereira-Dias, et al. "Ventilator-associated pneumonia in critically ill patients with COVID-19” 11 January 2021.

[15] S.Betlejewski, A.Betlejewski „The influence of nasal flow aerodynamics on the nasal physiology” 2008.

[16] M.D’Amato ”The impact of cold on the respiratory tract and its consequences to respiratory health” 30 May 2018.

[17] M.Wallin et al.  „Tidal volumes: cold and dry or warm and humid, does it matter?”.

[18] G.A.Plotnikow, M.Accoce, et al  „Humidification and heating of inhaled gas in patients with artificial airway. A narrative review”  January -March 2018.

[19] J.C. Van Oostdam „Effect of breathing dry air on structure and function of airways” July 1986.

[20] J.Carvill „Thermodynamics and heat transfer” 1993.

[21] S.Wernersson, G. Pejler „Mast cell secretory granules: armed for battle” N.R. Immu. 2014; 14: 478–494.

[22] M.L.Taylor, D.D. Metcalfe „Mast cells in allergy and host defense” Allergy Asthma P. 2001; 22: 115–119.

[23] G. Horstmann, et al „Influence of temperature and decreasing water content of inspired air on the ciliated bronchial epithelium, Acta Oto-Laryn 84, 1977, 124–131.

[24] H.O.Koskela „Cold air-provoked respiratory symptoms: the mechanisms and management” 01 Apr 2007.

[25] D.F.Proctor, D.L.Swift.”Temperature and water vapor adjustment. In:Respiratory Defense Mechanisms” 1977, 95–125.

[26] C.C. W. Hsia et al. ”Evolution of Air Breathing: Oxygen Homeostasis and the Transitions from Water to Land and Sky” April 2013.

[27] D.A.Kaminsky et al. ”Effects of Cool, Dry Air Stimulation on Peripheral Lung Mechanics in Asthma” 12 June 1998.

[28] P. Webb „Air temperatures in respiratory tracts of restingsubjects in cold” Novem 1951.

[29] M. Tobi, „Principles and practice of mechanical ventilation. 2nd edition. 2006. 1109–1115.

[30] H.O.Koskela „Cold air-provoked respiratory symptoms: themechanisms and management” 01 Apr 2007.

[31] The Mast Cell Disease Society, Inc. (TMS) „Symptoms and Triggers of Mast Cell Activation”.

[32] D.D.Metcalfe, et al. „Mast cells.” Physiol Rev 1997; 77: 1033–1079.

[33] American Academy of Allergy, Asthma & Immunology „Mast Cell Activation Syndrome (MCAS)”.

[34] M.Frieri, et al  ”Mast cell activation syndrome: a review” February 2013.

[35] M.Krystel-Whittemore et al. „Mast Cell: A Multi-Functional Master Cell” 06 Jan 2016.

[36] J.S. Erjefält "Mast cells in human airways: the culprit?” 2014.


[37] P.Soler et al. „Role of mast cells in the pathogenesis of hypersensitivity pneumonitis” Aug 1987.

[38] A.F. Walls et al „Mast cell tryptase and histamine concentrations in bronchoalveolar lavage fluid from patients with interstitial lung disease” August 1991.

[39] M.Metz, M.A. Grimbaldeston, S.Nakae et al. „Mast cells in the promotion and limitation of chronic inflammation” Immunol Rev 2007; 217: 304–328.

[40] A.St John et al. „Innate immunity and regulation by mast cells” 1 May 2013.

[41] J.Kope?-Szl?zak „Mast cells and their role in immunity and cancer” 2015.

[42] P.J. Barnes „Histamine receptors in the lung” 1991.

[43] X.Xiang et al. „Neutrophil histamine contributes to inflammation in mycoplasma pneumonia” December 2006.

[44] A.C. Rosa, R. Fantozzi ”The role of histamine in neurogenic inflammation”  Sept 2013.

[45]  M. Jutel,et al „Histamine in allergic inflammation and immune modulation”  May 2005.

[46] W. Lieberman-Cribbin, at al. „The impact of asthma on mortality in patients with COVID-19” 2020.

[47] R.S. Hotchkiss et al. „Sepsis and septic shock” 30 June 2016.

[48] J.I.M. Blanco „Antihistamines and azithromycin as a treatment for COVID-19 on primary health care – A retrospective observational study in elderly patients” April 2021.

[49] L.R.Reznikov et al "Identification of antiviral antihistamines for COVID-19 repurposing” 29 Jan 2021.

[50] M.Urb et al. „The Role of Mast Cells in the Defence against Pathogens” 26 April 2012.

[51] D.Ragab et al. „The COVID-19 Cytokine Storm; What We Know So Far” 16 June 2020.

[52] H.J.M.Lemmens, J.G. Brock-Utne „Heat and moisture exchange devices: are they doing what they are supposed to do?” February 2004.

[53] M. Kelly et al. „Heated humidification versus heat and moisture exchangers for ventilated adults and children” 14 Apr 2010.

[54] R. Poopalalingam, M.Goh, Y.W. Chan „The effect of heat and moisture exchanger and gas flow on humidity and temperature in a circle anaesthetic system” November 2002.

[55] D.Chiumello et al. „Effect of body mass index in acute respiratory distress syndrome” 01 January 2016.

[56] C.Anger et al. „[Characteristics of the relative humidity and temperature in the inspiratory part of the Dräger circle system and their influence on the function of the ciliary epithelium]” February 1990.

[57] G.I. Bardoczky et al. „Large tidal volume ventilation does not improve oxygenation in morbidly obese patients during anesthesia” August 1995.

[58] W.J. Schnedl et al. „Diamine oxidase supplementation improves symptoms in patients with histamine intolerance” December 2019.